Ocata Therapeutics Inc fka OCAT

[lasers]

We are waiting on the results for the 150K Cohort3 which was approved for completion in July 2013

http://www.advancedcell.com/news-and-media/press-releases/act-secures-approval-from-data-safety-monitoring-board-to-complete-third-patient-cohort-in-all-three-clinical-trials/index.asp

MARLBOROUGH, Mass. — July 17, 2013 – Advanced Cell Technology, Inc.(“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the company’s three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of remaining two patients in the third cohort of each of the three clinical trials. The decision follows an interim review by the DSMB six weeks after the first patient was treated in the third cohort of each trial. ACT will proceed with screening and enrollment for the patients who, in keeping with trial protocol, will be injected with 150,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

“We are pleased that the first patients treated with the higher dose of RPE cells are doing well and the DSMB sees fit for enrollment to continue in all three clinical trials,” commented Gary Rabin, chairman and CEO of ACT. “Even with several patients failing laboratory evaluations late in the inclusion/exclusion review process, which is not atypical in clinical trials, we have four of the six patient surgeries for the third cohorts scheduled, with two remaining to complete screening. We are confident that all surgeries will be performed in ample time for a complete data review at the company’s Ophthalmic Advisory Board meeting in early October, where Phase 2 trial designs will be discussed.”